Nutex Health Inc (NUTX)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $1.19B
Last updated: Nov 17, 2026 at 4:15 PM ET
Nutex Health Inc (NUTX) Statistics
Nutex Health (NUTX) has a market cap of $1.19B and an enterprise value of $1.27B. Its return on invested capital of 32.44% compares with a 8.61% median across 8 similar companies. Revenue fell 18.82% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 6.72% above the market cap, as debt exceeds cash.
| Market Cap | $1.19B |
|---|---|
| Enterprise Value | $1.27B |
| Latest price (Nov 17, 2026) | $174.51 |
Key Dates
The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.5x and 2.7x.
| P/E Ratio | 7.7x |
|---|---|
| Forward P/E | 6.2x |
| P/S Ratio | 1.5x |
| Forward P/S | 1.4x |
| P/B Ratio | 2.7x |
| P/TBV Ratio | 3.0x |
| P/FCF Ratio | 4.8x |
| P/OCF Ratio | 4.6x |
| PEG Ratio | 0.4 |
Enterprise Valuation
Counting debt and cash, the company is valued at 3.8x EBITDA and 5.1x free cash flow.
| EV / Earnings | 5.5x |
|---|---|
| EV / Sales | 1.6x |
| EV / EBITDA | 3.8x |
| EV / EBIT | 4.1x |
| EV / FCF | 5.1x |
Price Statistics
The stock is up 62.93% over 52 weeks and trades 13.40% below its 50-day average.
| Beta (1Y) | 1.67 |
|---|---|
| 52-Week Change | +62.93% |
| 1-Month Change | -8.75% |
| 3-Month Change | -8.45% |
| 6-Month Change | +38.07% |
| 5-Year Change | -66.62% |
| 10-Year Change | -95.89% |
| Total Return (1Y) | +62.93% |
| Total Return (3Y CAGR) | +71.32% |
| Total Return (5Y CAGR) | -21.90% |
| Return vs SPY (1Y) | +64.36% |
| Max Drawdown (1Y) | -54.32% |
| Max Drawdown (3Y) | -87.94% |
| Sharpe Ratio (1Y) | 0.64 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $201.51 |
| 200-Day Average | $152.18 |
| 52-Week Range | $83.99 to $226.16 |
| RSI (14 Days) | 41.6 |
| Average Volume (20 Days) | 139.96K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.76x current liabilities, and total debt is 0.76x shareholder equity.
| Current Ratio | 4.76x |
|---|---|
| Quick Ratio | 4.72x |
| Debt / Equity | 0.76x |
| Debt / EBITDA | 0.99x |
| Debt / FCF | 1.33x |
| Interest Coverage | 16.22x |
Returns and Efficiency
Return on invested capital is 32.44% over the last 12 months, against a 5-year average of -30.14%.
| Return on Equity (ROE) | 53.50% |
|---|---|
| Return on Assets (ROA) | 22.57% |
| Return on Invested Capital (ROIC) | 32.44% |
| Return on Capital Employed (ROCE) | 34.61% |
| ROE (5Y Average) | -49.75% |
| ROA (5Y Average) | -6.87% |
| ROIC (5Y Average) | -30.14% |
| Asset Turnover | 0.80x |
| Inventory Turnover | 42.68x |
| Receivables Turnover | 2.22x |
| Cash Conversion Cycle | 150 days |
Taxes
Income tax took 20.22% of pretax income over the last 12 months.
| Income Tax (TTM) | $59.05M |
|---|---|
| Effective Tax Rate | 20.22% |
Scores
NUTX has an Altman Z-Score of 3.63, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.63 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 8 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue was $796.53M over the last 12 months.
| Revenue | $796.53M |
|---|---|
| Revenue Growth (YoY) | -18.82% |
| Gross Profit | $380.67M |
| Operating Income | $311.00M |
| Pretax Income | $292.08M |
| Net Income | $233.03M |
| EBITDA | $332.89M |
| EBIT | $311.27M |
| Reported EPS (TTM) | $22.65 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 42.29% of the $1.03B in total assets.
| Cash and Equivalents | $249.91M |
|---|---|
| Total Debt | $330.00M |
| Net Debt | $80.09M |
| Net Debt Per Share | $11.67 |
| Working Capital | $500.30M |
| Shareholder Equity | $435.57M |
| Book Value Per Share | $63.49 |
| Tangible Book Value | $401.39M |
| Tangible Book Per Share | $58.51 |
| Total Assets | $1.03B |
| Total Liabilities | $491.47M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $10.35M of capital spending, operating cash flow left $248.10M of free cash flow.
| Operating Cash Flow | $258.45M |
|---|---|
| Capital Expenditures | $10.35M |
| Free Cash Flow | $248.10M |
| FCF Per Share | $36.23 |
| Depreciation and Amortization | $21.62M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 39.04%, against a 5-year average of -17.63%.
| Gross Margin | 47.79% |
|---|---|
| Operating Margin | 39.04% |
| Pretax Margin | 36.67% |
| Net Margin | 29.26% |
| EBITDA Margin | 41.79% |
| EBIT Margin | 39.08% |
| FCF Margin | 31.15% |
| Gross Margin (5Y Average) | 33.36% |
| Operating Margin (5Y Average) | -17.63% |
| Net Margin (5Y Average) | -24.74% |
Growth
Revenue grew 58.62% a year over 3 years.
| Revenue Growth (3Y CAGR) | +58.62% |
|---|---|
| Revenue Growth (5Y CAGR) | +26.14% |
| FCF Growth (3Y CAGR) | +89.70% |
| FCF Growth (5Y CAGR) | +57.32% |
Dividends and Yields
NUTX does not pay a dividend. Its free cash flow yield is 20.72%.
| Earnings Yield | 12.99% |
|---|---|
| FCF Yield | 20.72% |
| Buyback Yield | 4.23% |
| Shareholder Yield | 11.40% |
Stock Splits
The last split was a 1-for-10 reverse split on Jul 3, 2024.
| Last Split Date | Jul 3, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 7 similar companies, NUTX has the lowest P/E.
P/E RatioPeer median 28.6x
P/S RatioPeer median 1.6x
ROICPeer median 8.61%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +16.84%
| P/E Ratio | 7.7x vs 28.6x median |
|---|---|
| P/S Ratio | 1.5x vs 1.6x median |
| ROIC | 32.44% vs 8.61% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -18.82% vs +16.84% median |
Analyst Forecast
Consensus estimates put revenue growth at 4.99% and EPS growth at 30.61% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +4.99% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +30.61% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NUTX
What is NUTX's market cap?
Nutex Health has a market cap of $1.19B. Its enterprise value, which adds debt and subtracts cash, is $1.27B.
What is NUTX's P/E ratio?
Nutex Health has a trailing P/E ratio of 7.7x and a forward P/E of 6.2x.
How many shares of NUTX are outstanding?
Nutex Health has 6.86M shares outstanding. The count is down 2.99% from a year earlier.
Does NUTX pay a dividend?
No. Nutex Health does not pay a dividend.
How much debt does NUTX have?
Nutex Health has $330.00M of total debt and $249.91M of cash and equivalents, a net debt position of $80.09M.
NUTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors